Quick Answer
Syndax Pharmaceuticals Inc reported Revenue From Contract With Customer Excluding Assessed Tax of $172.35 million for the year ending 2025.
- Syndax Pharmaceuticals Inc showed an increase of +627.8% in Revenue From Contract With Customer Excluding Assessed Tax from 2024 to 2025.
- This data is from Syndax Pharmaceuticals Inc's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 10 years of available data (2016 to 2025), Syndax Pharmaceuticals Inc's Revenue From Contract With Customer Excluding Assessed Tax has grown by 14,027.2%.
- Historical annual values: Fiscal year 2025: $172.35 million | Fiscal year 2024: $23.68 million | Fiscal year 2023: $0.00 | Fiscal year 2022: $0.00 | Fiscal year 2021: $139.71 million | Fiscal year 2020: $1.52 million | Fiscal year 2019: $1.52 million | Fiscal year 2018: $1.52 million | Fiscal year 2017: $2.11 million | Fiscal year 2016: $1.22 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: